Phillip P. Chan - Apr 3, 2023 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
Chief Executive Officer
Signature
/s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan
Stock symbol
CTSO
Transactions as of
Apr 3, 2023
Transactions value $
$87,688
Form type
4
Date filed
4/5/2023, 05:00 PM
Previous filing
Dec 9, 2022
Next filing
Jul 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Options Exercise $87.7K +30.5K +3.4% $2.88 928K Apr 3, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTSO Stock Option (right to buy) Options Exercise $0 -30.5K -100% $0.00* 0 Apr 3, 2023 Common Stock 30.5K $2.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (a) the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
F2 (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: (a) 24,000 RSUs granted on April 12, 2021 and unvested on the date hereof and (b) 52,667 RSUs granted on August 10, 2022 and unvested as of the date hereof; and
F3 (continued from footnote 3) (c) 635,112 shares of the Issuer's common stock owned by the reporting person, inclusive of the 30,500 shares of the Issuer's common stock reported on this Form 4.
F4 These stock options were originally granted on April 4, 2013 and became exercisable at the discretion of the Board of Directors of the Company upon the achievement of certain milestones connected to the Company's operations.